Background: Therapeutic strategies modulating the deleterious immune response underlying immune reconstitution inflammatory syndrome (IRIS) are warranted. It has been suggested that CCR5 antagonists might be beneficial in the management of IRIS associated with progressive multifocal leukoencephalopathy (PML). Here, we analyzed the expression of CCR5 on immune cells infiltrating PML-IRIS lesions in 5 HIV-infected patients.
Methods: We performed a retrospective cross-sectional study of all HIV-infected patients diagnosed with PML-IRIS in the Toulouse University Hospital, France, between January 2000 and January 2010. Brain biopsies were collected from 5 patients and their histopathological features were compared to those of 4 HIV-infected patients with classical PML. All biopsies were performed before any steroid therapy.
Results: In all cases, histological analysis revealed demyelinating lesions and the presence of JC virus-infected cells, confirming PML. In PML-IRIS patients, the inflammatory infiltrates were dominated by CD3+ T cells, which were nearly exclusively composed of CD8+ T cells. Double stainings of CCR5 with CD3, CD8, CD20 (B-cells) and Iba-1 (Macrophages) showed that most of the perivascular and parenchymal infiltrating CD8+ T cells strongly expressed CCR5 on their surface. Macrophages also express CCR5, but to a lesser extent. Classical PML lesions were devoid of inflammatory infiltrates.
Conclusions: Cytotoxic CD8+ T cells that dominate the inflammatory response in patients with PML-IRIS highly express CCR5. By inhibiting migration and/or activation of effector cells expressing CCR5, maraviroc might be beneficial to prevent and/or treat the deleterious inflammatory reaction that occurs during immune recovery in HIV-infected PML patients. This possibility deserves further studies.